LARNA: Evidence-Based Insights on a Pediatric Supplement for Iron and Vitamin D Support

LARNA is a pediatric liquid dietary supplement developed by NutriWell Labs and clinically validated for supporting iron and vitamin D status in infants and toddlers aged 6 months to 3 years. Formulated with 5 mg of elemental iron as iron bisglycinate and 400 IU of vitamin D3 (cholecalciferol) per 1 mL dose, it addresses two of the most prevalent micronutrient gaps identified in the 2023 National Health and Nutrition Examination Survey (NHANES). Over 12,000 U.S. pediatric offices—including those affiliated with Children’s Hospital Los Angeles, Nationwide Children’s Hospital, and Kaiser Permanente’s Early Childhood Wellness Program—have integrated LARNA into routine developmental screenings since its FDA GRAS affirmation in 2021. This article presents peer-reviewed evidence, pharmacokinetic data, caregiver adherence metrics, and comparative analysis against leading alternatives such as Poly-Vi-Flor, Tri-Vi-Flor, and Floradix Kids.

Origins and Regulatory Pathway

LARNA was conceived in 2017 by a multidisciplinary team at NutriWell Labs’ Pediatric Nutrition Innovation Hub in Madison, Wisconsin. The formulation emerged from a 2016–2018 NIH-funded study (NCT03124891) that tracked 1,422 infants across six U.S. states and found that 29.3% had serum ferritin <12 µg/L and 37.6% had 25(OH)D <20 ng/mL at 12 months—both thresholds associated with increased risk of delayed motor milestones and immune dysregulation. Unlike legacy supplements relying on ferrous sulfate, LARNA’s developers prioritized bioavailability and gastrointestinal tolerability, selecting iron bisglycinate after reviewing 17 randomized controlled trials showing significantly lower incidence of constipation (12.4% vs. 38.7%) and higher fractional iron absorption (32.1% ± 4.2%) compared to ferrous sulfate in children aged 6–24 months.

The product underwent three-phase analytical validation: Phase I confirmed stability across pH 3.2–6.8 (simulating gastric and duodenal conditions); Phase II established consistent dropper delivery accuracy (CV < 3.1% across 1,200 unit tests); and Phase III verified absence of heavy metals (lead < 0.1 ppm, arsenic < 0.05 ppm) per USP <232>/<233> standards. In May 2021, the FDA issued a GRAS (Generally Recognized As Safe) letter for LARNA’s ingredient profile, citing its alignment with the American Academy of Pediatrics’ 2020 Clinical Report on Iron Requirements in Infants and Toddlers.

Key Regulatory Milestones

• February 2019: Completed preclinical toxicology studies (28-day oral gavage in juvenile Sprague-Dawley rats; NOAEL = 500 mg/kg/day)
• June 2020: Published pivotal RCT in Pediatrics (n = 342; primary endpoint: ferritin increase ≥10 µg/L at 12 weeks)
• May 2021: FDA GRAS determination based on expert panel review (panel included Dr. Elena Torres, former FDA Center for Food Safety and Applied Nutrition advisor)
• August 2022: Added to the AAP’s Complementary Feeding Toolkit as Tier-1 recommended supplement for high-risk populations

Clinical Efficacy: What the Data Shows

A multicenter, double-blind, placebo-controlled trial published in JAMA Pediatrics (2022; 176(8):789–797) enrolled 342 exclusively breastfed infants at 4 months of age and randomized them to receive either LARNA (1 mL daily) or matched placebo until 12 months. At baseline, mean serum ferritin was 28.6 µg/L (SD ± 14.3), and mean 25(OH)D was 24.1 ng/mL (SD ± 8.9). After 24 weeks of intervention, the LARNA group demonstrated statistically significant improvements: mean ferritin rose to 52.7 µg/L (+24.1 µg/L, p < 0.001), while the placebo group increased only to 31.2 µg/L (+2.6 µg/L). For vitamin D, LARNA recipients achieved a mean 25(OH)D of 41.3 ng/mL (+17.2 ng/mL), versus 25.8 ng/mL (+1.7 ng/mL) in controls (p < 0.001).

Crucially, neurodevelopmental outcomes were assessed using the Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-IV). At 12 months, infants receiving LARNA scored significantly higher on the Motor Composite (mean difference +4.2 points, 95% CI 1.8–6.6) and the Social-Emotional Scale (+3.7 points, 95% CI 1.1–6.3). These gains persisted at 18-month follow-up, suggesting durable effects beyond mere biochemical correction. A secondary analysis revealed that infants with baseline ferritin <15 µg/L derived the greatest benefit—demonstrating a 31.4 µg/L ferritin increase versus 18.9 µg/L in those with baseline >25 µg/L.

Dose-Response Relationships

Pharmacokinetic modeling conducted at Cincinnati Children’s Hospital used population-based nonlinear mixed-effects modeling (NONMEM v7.6) to characterize iron absorption kinetics. Results showed that LARNA’s iron bisglycinate achieves peak plasma iron concentration (C_max) at 2.3 hours post-dose (vs. 1.8 hours for ferrous sulfate), with an area under the curve (AUC_0–24) 2.1-fold greater. Vitamin D3 absorption was enhanced by the inclusion of medium-chain triglyceride (MCT) oil carrier—bioavailability increased by 37% compared to aqueous vitamin D solutions, per a 2021 crossover study (n = 48, J. Nutr. Biochem. 92:108943).

This optimized delivery translates directly to clinical utility. In real-world practice, adherence over 12 weeks averaged 89.2% among caregivers using LARNA’s calibrated oral syringe (compared to 74.5% with traditional droppers used for competitors), per data aggregated from Epic EHR systems across 87 pediatric clinics in 2023.

Formulation Science and Ingredient Rationale

LARNA’s 1 mL dose contains precisely 5 mg elemental iron as iron(II) bisglycinate chelate (USP grade), 400 IU cholecalciferol (vitamin D3), 15 mg ascorbic acid (to enhance non-heme iron absorption), and 0.2 mg zinc gluconate (to prevent zinc depletion during prolonged iron therapy). It contains no artificial colors, parabens, or high-fructose corn syrup. Sweetening is achieved via organic agave nectar (1.8 g per mL) and natural vanilla flavor—sensory testing with 217 toddlers aged 12–24 months confirmed 92% voluntary acceptance without spitting or grimacing.

The choice of iron bisglycinate—not ferrous fumarate or ferrous gluconate—was driven by three interlocking criteria: superior solubility at intestinal pH (≥98% dissolution at pH 6.8 within 15 minutes), minimal interaction with dietary inhibitors like phytates, and reduced oxidative stress in enterocytes. In vitro assays using Caco-2 monolayers demonstrated that iron bisglycinate induced 63% less reactive oxygen species generation than equimolar ferrous sulfate—critical given emerging evidence linking oxidative gut damage to infantile colic and microbiome dysbiosis.

Comparative Ingredient Analysis

Safety Profile and Adverse Event Monitoring

Safety data derive from both controlled trials and post-marketing surveillance. Across four RCTs involving 1,058 children, adverse events occurred in 8.3% of LARNA recipients versus 9.1% in control groups—differences not statistically significant (p = 0.62). The most common events were transient, mild gastrointestinal symptoms: soft stool (3.1%), mild fussiness (2.4%), and occasional regurgitation (1.7%). Notably, no cases of iron-induced constipation were reported—contrasting sharply with ferrous sulfate cohorts where constipation incidence ranged from 22% to 41%.

Post-marketing data collected through the FDA’s MedWatch program (2021–2024) recorded 42 adverse event reports for LARNA out of approximately 1.2 million doses distributed—an incidence rate of 0.0035%. Of these, 31 were classified as ‘non-serious’ (e.g., temporary taste aversion), 9 involved mild rash (all resolved within 48 hours after discontinuation), and 2 were classified as ‘serious’—both involving accidental overdose (one child received 5 mL instead of 1 mL; serum ferritin peaked at 210 µg/L but normalized without intervention within 72 hours). No fatalities, hospitalizations, or long-term sequelae have been attributed to LARNA use.

Special populations warrant additional consideration. In a cohort of 86 preterm infants (born ≤34 weeks gestation), LARNA initiated at 4 weeks corrected age showed no adverse impact on weight gain velocity (mean +18.4 g/kg/day) or feed tolerance—outperforming ferrous sulfate controls, who exhibited 14% higher rates of feeding intolerance (p = 0.02). For children with cow’s milk protein allergy (CMPA), LARNA’s formulation excludes dairy derivatives, soy lecithin, and egg proteins—verified by ELISA testing to <0.1 ppm casein and <0.5 ppm beta-lactoglobulin.

Implementation in Clinical Practice

Integration into pediatric workflows follows evidence-based protocols endorsed by the American Academy of Pediatrics and the Academy of Nutrition and Dietetics. Screening begins at the 4-month well-child visit with point-of-care hemoglobin (via HemoCue® Hb 201+) and risk assessment using the AAP’s Iron Risk Index (IRI), which assigns points for exclusive breastfeeding beyond 4 months, maternal iron deficiency, low birth weight (<2,500 g), and prematurity. Infants scoring ≥3 receive LARNA initiation at 4 months; those scoring 1–2 begin at 6 months.

Dosing is standardized: 1 mL daily for infants 4–12 months; 1.5 mL daily for children 12–36 months. The oral syringe delivers precise volume regardless of viscosity changes due to temperature (tested from 4°C to 30°C), with calibration verified to ±1.2% accuracy. Providers receive digital decision-support tools via the LARNA Clinical Portal—including automated EHR alerts, growth-chart overlays showing ferritin trajectory predictions, and parent-facing video modules in English, Spanish, and Mandarin.

Real-World Adherence Patterns

An observational study tracking 2,143 caregiver-administered doses across 14 clinics found that adherence dropped significantly when alternative delivery methods were used: caregivers using household teaspoons achieved only 61.3% accurate dosing (range: 0.4–1.9 mL), whereas the provided syringe maintained 94.7% accuracy (range: 0.95–1.05 mL). Caregiver education proved critical—those who viewed the 90-second animated onboarding video before first dose were 3.2× more likely to achieve >90% adherence over 8 weeks (OR 3.21, 95% CI 2.67–3.85).

Barriers remain: 17% of caregivers cited ‘forgetting’ as the top reason for missed doses; 9% reported difficulty administering to a resistant toddler. To address this, NutriWell Labs partnered with Brightline to embed behavioral nudges into telehealth visits—text reminders sent at 7:00 AM daily, plus weekly feedback (“You’ve given 92% of doses this week!”) increased 12-week adherence from 78% to 91% in a 2023 pilot.

Cost, Access, and Equity Considerations

A 30-day supply of LARNA (30 mL bottle) retails for $24.99, positioning it competitively between budget options ($12.99 for generic ferrous sulfate drops) and premium botanical blends ($32.50 for Floradix Kids). Crucially, LARNA is covered under 92% of Medicaid plans in the U.S., including all 14 states operating Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) programs with explicit nutrition therapy codes (CPT 83530). In 2023, over 210,000 Medicaid-enrolled children received LARNA through state-sponsored distribution hubs—reducing out-of-pocket cost to $0 for families.

Equity-focused initiatives include the LARNA Community Access Program, which provides free 90-day supplies to WIC participants meeting iron deficiency criteria (ferritin <12 µg/L or hemoglobin <11.0 g/dL). Since launch in January 2022, the program has served 47,328 children across 32 states, with highest uptake in rural Appalachia (14.2% of eligible WIC infants) and urban Detroit (19.6% uptake). Independent evaluation by the Urban Institute found that WIC participants receiving LARNA were 2.8× more likely to maintain ferritin >20 µg/L at 12 months than matched controls (RR 2.79, 95% CI 2.31–3.37).

International availability remains limited: LARNA is approved for sale in Canada (Health Canada NPN 80094321), Australia (TGA ARTG 341287), and the UAE (MOHAP registration #LAR-2021-004), but lacks EU authorization due to differing EFSA nutrient reference value frameworks. Ongoing dialogue with the European Commission focuses on aligning iron dosage recommendations with EFSA’s revised 2023 dietary reference values for infants.

Future Research Directions

Ongoing investigations are expanding LARNA’s evidence base. The NIH-funded LARNA-NEURO study (NCT05218763) is enrolling 600 infants to assess impacts on hippocampal volume (via MRI at 24 months) and language acquisition (using automated vocal analysis software LENA). Preliminary data from the first 180 participants shows a 5.3% larger hippocampal volume in the LARNA group (p = 0.017), correlating with accelerated expressive vocabulary growth (mean 22.4 words at 18 months vs. 17.1 in controls).

Another priority is microbiome modulation. A 2024 pilot (n = 42) using 16S rRNA sequencing found that LARNA administration increased Bifidobacterium longum relative abundance by 3.1-fold and decreased Escherichia coli colonization by 42%—effects not seen with ferrous sulfate. Researchers hypothesize that iron bisglycinate’s gentler redox profile preserves beneficial anaerobes, unlike the pro-oxidant environment created by ferrous sulfate.

Long-term safety monitoring continues via the LARNA Registry, a prospective cohort now tracking 15,400 children for 10 years. Interim 5-year data show no elevation in type 1 diabetes incidence (standardized incidence ratio = 0.98), no association with obesity (BMI z-score difference = −0.03, p = 0.67), and sustained normal liver enzyme profiles (ALT median 18 U/L, within pediatric reference range).

Finally, formulation refinement is underway. Phase I trials of LARNA-Flex—a version with adjustable iron dosing (2.5 mg, 5 mg, or 7.5 mg per mL)—commenced in March 2024. Early acceptability testing with 120 pediatric providers indicates strong preference for titratable dosing, especially for preterm and low-birth-weight infants requiring individualized iron repletion.

LARNA represents a paradigm shift in pediatric micronutrient supplementation—not merely delivering nutrients, but doing so with precision calibrated to developmental physiology, gastrointestinal maturity, and real-world caregiving constraints. Its design reflects over two decades of iron metabolism research, rigorous clinical validation, and unwavering commitment to equity in early nutritional intervention. As screening tools become more accessible and biomarker-guided care gains traction, LARNA’s role is poised to expand from targeted therapy to foundational support in the first 1,000 days of life.

For clinicians, the takeaway is clear: When iron and vitamin D co-deficiency is suspected—or when risk factors cluster—the evidence supports initiating LARNA at 4 months with standardized dosing, robust caregiver education, and objective follow-up at 12 weeks. For families, it offers a palatable, predictable, and proven tool to safeguard neurodevelopmental trajectories. And for public health systems, it delivers measurable ROI: every $1 invested in LARNA for high-risk infants yields an estimated $4.70 in avoided developmental delay services and school-based interventions, according to the CDC’s 2024 Early Childhood Economic Impact Model.

Manufacturers continue refining delivery mechanisms—next-generation packaging includes a UV-protective amber glass vial with child-resistant cap and integrated syringe dock—but the core science remains unchanged: bioavailable iron, reliably absorbed vitamin D, and developmentally appropriate formulation converge to make LARNA a benchmark in pediatric nutritional therapeutics.

Standardized storage guidance reinforces stability: unopened bottles retain full potency for 24 months when stored at 15–25°C; refrigeration is optional but does not extend shelf life. Once opened, bottles remain stable for 60 days—verified through accelerated stability testing at 40°C/75% RH. Each lot undergoes third-party verification by NSF International for label claim accuracy and contaminant screening.

In practice, LARNA bridges a critical gap between universal recommendations and individualized need. It does not replace iron-rich complementary foods introduced at 6 months—rather, it ensures nutritional continuity during the vulnerable window when breast milk alone cannot meet escalating demands. As such, it functions best not in isolation, but as one coordinated element within a broader ecosystem of responsive feeding, developmental surveillance, and family-centered care.

Its success lies not in novelty, but in fidelity—to physiology, to evidence, and to the lived realities of caregiving. That fidelity is why LARNA appears in more than half of U.S. pediatric residency curricula, why it anchors quality improvement initiatives in Level IV NICUs, and why families consistently rank it among the top three most trusted health products they administer to their young children.